Clinical Trials Logo

Sepsis, Severe clinical trials

View clinical trials related to Sepsis, Severe.

Filter by:

NCT ID: NCT06368336 Completed - Sepsis Clinical Trials

Health Related Quality of Life After Intensive Care for Sepsis, a National Cohort Study.

Start date: January 1, 2008
Phase:
Study type: Observational [Patient Registry]

The study aims to map the health-related quality of life (HRQoL) after intensive care for Sepsis with the hypothesis that it will be lower than that in the general population. The investigators also want to identify factors that are associated with low HRQoL, to see if those are available for interventions from the health care system and society to improve quality of life after treatment for sepsis in the intensive care unit (ICU).

NCT ID: NCT06178822 Recruiting - Sepsis Clinical Trials

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

BIOSEP
Start date: October 25, 2022
Phase:
Study type: Observational [Patient Registry]

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

NCT ID: NCT05975671 Recruiting - Sepsis Clinical Trials

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

REVAMP
Start date: August 21, 2023
Phase: N/A
Study type: Interventional

The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU). There are two groups of subjects in this study: PICU clinicians/sepsis stakeholders and patients admitted to one of the participating PICUs during the study period. The intervention will at a minimum include: - Implementation of a clinical guideline indicating when vancomycin should and should not be used - Unit-level feedback on overall vancomycin use within and across centers - Clinician education.

NCT ID: NCT05836272 Recruiting - Sepsis, Severe Clinical Trials

Early Administration of Norepinephrine in Sepsis

EA-NE-TUN
Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

The management of septic states includes, in addition to the specific treatment (antimicrobials and eradication of the source), a restoration of the hemodynamic disorders and assistance of the failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of Noepinephrine (NE) when the target mean arterial pressure (MAP) is not reached after optimizing the intravascular volume. Recently, several studies have supported the interest of early NE on MAP, cardiac output and mortality. It is therefore tempting to restrict fluid administration even in the initial phase of hemodynamic management of severe sepsis by starting NE earlier.

NCT ID: NCT05540808 Not yet recruiting - Sepsis, Severe Clinical Trials

The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis

Start date: February 10, 2023
Phase:
Study type: Observational

The etiological diagnosis of sepsis is the key to guide clinical treatment. Metagenomic sequencing (mNGS) is very suitable for the diagnosis of sepsis due to its rapid, accurate and not easy to be disturbed by the environment. However, the conventional pathogen mNGS has potential risks such as low detection rate, loss of intracellular bacteria and fungi. At present, the latest fully targeted pathogen capture mNGS technology makes up for the shortcomings of conventional methods by bidirectional enrichment of pathogen nucleic acids. The aim of this study was to explore the value of fully targeted pathogen capture mNGS in improving etiological diagnosis in patients with sepsis compared with conventional methods.

NCT ID: NCT05467605 Completed - Sepsis, Severe Clinical Trials

Effect of Probiotics on Cytokines in Sepsis in Children

Start date: July 22, 2022
Phase: N/A
Study type: Interventional

To assess the effect of probiotics on cytokine's level(interleukin 6 and Transforming growth factor-β1)in children admitted to PICU with sepsis.

NCT ID: NCT05442710 Recruiting - Sepsis, Severe Clinical Trials

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

ReActiF-ICE
Start date: July 24, 2022
Phase: Phase 2
Study type: Interventional

Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care. This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)

NCT ID: NCT05357339 Recruiting - Sepsis Clinical Trials

Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The sublingual microcirculation is impaired in sepsis and septic shock. Sidestream dark field imaging technology has been developed into a clinical tool to help the clinician assess the microcirculation at the bedside. The ideal resuscitation fluid has not been identified. The investigators aim to use this new bedside technology to establish the microcirculation properties of two popular resuscitation fluids.

NCT ID: NCT05246969 Completed - Sepsis Clinical Trials

Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage

Start date: June 1, 2017
Phase:
Study type: Observational

The study aims to evaluate the suitability of the SOFA score implemented by the Sepsis 3 guideline to detect sepsis in patients suffering from subrarachnoid hemorrhage.

NCT ID: NCT04979767 Recruiting - Sepsis Clinical Trials

Function of Circulating Exosomes in Sepsis-induced Immunosuppression

Start date: April 15, 2021
Phase:
Study type: Observational

This is a single-center prospective bio-specimen analysis and observational study aiming to define immune pathways disrupted in bacterial sepsis and to identify clinically useful biomarkers of immune status.